World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
112
Citations
86820
World Ranking
442
National Ranking
271

Medicine

D-Index
112
Citations
86821
World Ranking
5039
National Ranking
2730

Charles G. Drake publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Charles G. Drake sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 521 publications — 91st percentile

91% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Charles G. Drake D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Charles G. Drake sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 112 D-Index — 91st percentile

91% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Charles G. Drake is affiliated with Columbia University in the United States and has contributed extensively to the fields of medicine and immunology. Their research encompasses oncology, pulmonary and respiratory medicine, immunology, molecular biology, and surgery, with a significant focus on cancer and immune-related topics.

The scientist's main areas of study include:

  • Medicine
  • Immunology and Microbiology

Within these broader disciplines, their subfields of expertise are:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Immunology
  • Molecular Biology
  • Surgery

Drake's research topics concentrate on cancer and immunotherapy, specifically:

  • Cancer Immunotherapy and Biomarkers
  • Prostate Cancer Treatment and Research
  • Immunotherapy and Immune Responses
  • Renal cell carcinoma treatment
  • Immune cells in cancer
  • Bladder and Urothelial Cancer Treatments
  • CAR-T cell therapy research

The scientist has published in several frequent venues, indicating a consistent presence in prominent journals:

  • Journal of Clinical Oncology
  • Cancer Research
  • The Prostate
  • Clinical Cancer Research
  • European Urology

Noteworthy recent papers authored or co-authored by Drake include:

  • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019 (2020, European Urology)
  • Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages (2021, Cell)
  • Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens (2020, Nature Biotechnology)
  • Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce (2020, Journal for ImmunoTherapy of Cancer)
  • Prostate carcinogenesis: inflammatory storms (2020, Nature reviews. Cancer)

The scientist maintains collaborative relationships with several frequent co-authors including:

  • Aleksandar Obradović
  • Andrea Califano
  • Matthew G. Chaimowitz
  • Matthew C. Dallos
  • Angelo M. De Marzo

Drake's publication record reflects a sustained focus on cancer immunotherapy, prostate cancer, and immune-based treatment strategies, contributing both to clinical and molecular understandings of cancer biology. Their work spans fundamental studies of tumor microenvironments and immune responses to translational research aimed at improving therapeutic interventions.

Best Publications

  • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

    Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger

  • Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

    Julie R. Brahmer;Scott S. Tykodi;Scott S. Tykodi;Laura Q.M. Chow;Wen Jen Hwu

  • Immune checkpoint blockade: a common denominator approach to cancer therapy

    Suzanne L. Topalian;Charles G. Drake;Drew M. Pardoll

  • Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

    Julie R. Brahmer;Charles G. Drake;Ira Wollner;John D. Powderly

  • A draft map of the human proteome

    Min Sik Kim;Sneha M. Pinto;Derese Getnet;Raja Sekhar Nirujogi

  • Inflammation in prostate carcinogenesis

    Angelo M. De Marzo;Angelo M. De Marzo;Elizabeth A. Platz;Siobhan Sutcliffe;Jianfeng Xu

  • Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

    Eugene D. Kwon;Charles G. Drake;Howard I. Scher;Karim Fizazi

  • Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

    Seng Ryong Woo;Meghan E Turnis;Monica V Goldberg;Jaishree Bankoti

  • Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

    Suzanne L Topalian;Charles G Drake;Drew M Pardoll

  • Role of LAG-3 in regulatory T cells.

    Ching Tai Huang;Creg J. Workman;Dallas Flies;Xiaoyu Pan

  • Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

    Diana Miao;Diana Miao;Claire A. Margolis;Claire A. Margolis;Wenhua Gao;Martin H. Voss;Martin H. Voss

  • LAG3 (CD223) as a cancer immunotherapy target.

    Lawrence P. Andrews;Ariel E. Marciscano;Charles G. Drake;Dario A. A. Vignali

  • Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.

    Jing Zeng;Alfred P. See;Jillian Phallen;Christopher M. Jackson

  • Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy

    Andrew B Sharabi;Andrew B Sharabi;Michael Lim;Michael Lim;Theodore L DeWeese;Theodore L DeWeese;Charles G Drake;Charles G Drake

  • Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer

    Tomasz M. Beer;Eugene D. Kwon;Charles G. Drake;Karim Fizazi

  • Mechanisms of immune evasion by tumors.

    Charles G. Drake;Elizabeth Jaffee;Drew M. Pardoll

  • Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma

    Sofia Lyford-Pike;Shiwen Peng;Geoffrey D. Young;Janis M. Taube

  • Cutting Edge: An In Vivo Requirement for STAT3 Signaling in TH17 Development and TH17-Dependent Autoimmunity

    Timothy J. Harris;Joseph F. Grosso;Hung Rong Yen;Hong Xin

  • Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?

    Charlene M Fares;Eliezer M Van Allen;Charles G Drake;James P Allison

  • Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

    Evan J. Lipson;William H. Sharfman;Charles G. Drake;Ira Wollner

  • Prostate cancer

    Unknown

Frequent Co-Authors

Emmanuel S. Antonarakis
Emmanuel S. Antonarakis University of Minnesota
Angelo M. De Marzo
Angelo M. De Marzo Johns Hopkins University School of Medicine
Drew M. Pardoll
Drew M. Pardoll Johns Hopkins University School of Medicine
George J. Netto
George J. Netto University of Alabama at Birmingham
Elizabeth A. Platz
Elizabeth A. Platz Johns Hopkins University
Janis M. Taube
Janis M. Taube Johns Hopkins University
Phuoc T. Tran
Phuoc T. Tran Johns Hopkins University School of Medicine
Tullia C. Bruno
Tullia C. Bruno University of Pittsburgh
Toni K. Choueiri
Toni K. Choueiri Harvard University
Michael A. Carducci
Michael A. Carducci Johns Hopkins University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to a variety of interdisciplinary career paths, including advanced nursing degrees that complement immunology expertise. Many professionals pursue nurse practitioner roles to gain hands-on clinical experience. For those considering this route, exploring the easiest np program options online can help balance rigorous immunology studies with practical nursing education.

Particularly for those interested in mental health, online psychiatric nurse practitioner programs offer specialized training that leverages an understanding of immune system interactions with psychological conditions. Programs known for the best pmhnp programs online often provide excellent clinical placements, crucial for real-world experience.

Cost is another significant factor for students and professionals advancing their education. Identifying the cheapest online pmhnp certificate programs can make pursuing specialized immunology-related healthcare careers more accessible and financially feasible.

Knowing the potential financial outcomes, such as how much a Doctor of Nursing Practice (DNP) can make, is essential when choosing a career pathway. Understanding the how much does a dnp make metric helps graduates make informed decisions about their education investments and professional goals within immunology and healthcare.

Best Scientists Citing Charles G. Drake

Trending Scientists

Recently Published Articles